<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693028</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr. 085-15</org_study_id>
    <nct_id>NCT02693028</nct_id>
  </id_info>
  <brief_title>Lactobacillus Reuteri Feasibility Study on Probiotic Treatment and Perinatal Microbiome</brief_title>
  <official_title>Lactobacillus Reuteri Feasibility Study on Probiotic Lozenges, Probiotic Chewing Gum and Probiotic Capsules and Perinatal Microbiome Seeding During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators want to investigate if the Lactobacillus Reuteri (probiotic bacteria) given to
      pregnant women can be found in different maternal compartments and in the first stool and
      oral swab collected immediately after birth of a newborn delivered by cesarean delivery.
      Investigators also want to explore if exposure to this Lactobacillus Reuteri alters the level
      of inflammation in different compartments of the mother and the infant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this project is to better understand the following issues:

        1. How does bacteria transmit from the mother to the fetus and placenta during pregnancy
           and to the infant during the first 2-6 weeks after birth?

        2. Does colonization of the pregnant mother and fetus/Child occur? How and when?

        3. Can orally given probiotic bacteria be found in the newborn 2-6 weeks after birth, and
           if so where?

        4. How is bacteria transported from the mother's intestinal lumen to the Child/fetus gut?

        5. What impact has these bacteria on the level of inflammation in maternal and fetal
           compartments, especially that normally seen in the intestine of all newborns?

        6. What impact has these bacteria in the bowel on a normal intestinal flora establishment?
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Lactobacillus reuteri in different compartments in the mother and the Child.</measure>
    <time_frame>Mother: From weeks 28-36 of pregnancy until 6 weeks post partum. Child: from birth till 4 years old.</time_frame>
    <description>Both cultivation techniques for the specific bacteria and metagenomic techniques will be used to be able to study both cultivable and non-cultivable bacteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of Toll-like receptor stimulated with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS after probiotic treatment and after placebo in different maternal and neonatal compartments.</measure>
    <time_frame>Mother: From weeks 28-36 of pregnancy until 6 weeks post partum. Child: from birth till 4 years old.</time_frame>
    <description>To evaluate whether there are differences in Toll-like receptor stimulation with Lactobacillus plantarum, Pseudomonas aeruginosa and LPS in different compartments between women treated with probiotic and the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of IL-6, IL-10, IL-1beta, MCP-1, IL-17, TNF-alfa after probiotic treatment and after placebo in different maternal and neonatal compartments.</measure>
    <time_frame>Mother: From weeks 28-36 of pregnancy until 6 weeks post partum. Child: from birth till 4 years old.</time_frame>
    <description>To evaluate whether there are differences in the levels of cytokines and chemokines in different compartments between women treated with probiotic and the placebo group</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>probiotic lozenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic chewing gum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo lozenge</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic lozenges</intervention_name>
    <description>The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
    <arm_group_label>probiotic lozenge</arm_group_label>
    <other_name>Lactobacillus reuteri lozenges</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo lozenges</intervention_name>
    <description>The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
    <arm_group_label>Placebo lozenge</arm_group_label>
    <other_name>&quot;non active&quot; treatment lozenges</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic capsules</intervention_name>
    <description>The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
    <arm_group_label>Probiotic capsule</arm_group_label>
    <other_name>Lactobacillus reuteri capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
    <arm_group_label>Placebo capsule</arm_group_label>
    <other_name>&quot;non active&quot; treatment capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic chewing gum</intervention_name>
    <description>The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.</description>
    <arm_group_label>Probiotic chewing gum</arm_group_label>
    <other_name>Lactobacillus reuteri chewing gum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single or multiple gestation

          -  Maternal age &gt; or = 18 y

        Exclusion Criteria:

          -  Known structural or chromosomal fetal malformation or abnormality

          -  Occlusive placenta previa, placenta previa in the anterior wall of the uterus,
             suspicion of accreta/increta/percreta infiltration

          -  Unable to understand information about the study due to language or severe mental
             disease

          -  Known Hepatitis B, C, HIV

          -  Known immunosuppressive illness if they are under treatment

          -  Treatment with cytokine, methotrexate or immunosuppresses cytotoxics in the last 6
             months before the study.

          -  Gastro-intestinal surgery including gastric bypass or huge intestinal resection.

          -  Anaphylactic shock

          -  Uterus malformation that occludes cervical Canal or uterus segment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Jacobsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Jacobsson, Professor</last_name>
    <phone>+46313436719</phone>
    <email>bo.jacobsson@obgyn.gu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Hallingstrom, midwife</last_name>
    <phone>+46 31 343 67 31</phone>
    <email>maria.hallingstrom@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Jacobsson, Professor</last_name>
      <phone>46705600162</phone>
      <email>bo.jacobsson@obgyn.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Yeganegi M, Leung CG, Martins A, Kim SO, Reid G, Challis JR, Bocking AD. Lactobacillus rhamnosus GR-1 stimulates colony-stimulating factor 3 (granulocyte) (CSF3) output in placental trophoblast cells in a fetal sex-dependent manner. Biol Reprod. 2011 Jan;84(1):18-25. doi: 10.1095/biolreprod.110.085167. Epub 2010 Sep 1.</citation>
    <PMID>20811016</PMID>
  </reference>
  <results_reference>
    <citation>Aagaard K, Ma J, Antony KM, Ganu R, Petrosino J, Versalovic J. The placenta harbors a unique microbiome. Sci Transl Med. 2014 May 21;6(237):237ra65. doi: 10.1126/scitranslmed.3008599.</citation>
    <PMID>24848255</PMID>
  </results_reference>
  <results_reference>
    <citation>Cobo T, Kacerovsky M, Palacio M, Hornychova H, Hougaard DM, Skogstrand K, Jacobsson B. Intra-amniotic inflammatory response in subgroups of women with preterm prelabor rupture of the membranes. PLoS One. 2012;7(8):e43677. doi: 10.1371/journal.pone.0043677. Epub 2012 Aug 20.</citation>
    <PMID>22916296</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonçalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev. 2002;8(1):3-13. Review.</citation>
    <PMID>11921380</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez E, Fernández L, Marín ML, Martín R, Odriozola JM, Nueno-Palop C, Narbad A, Olivares M, Xaus J, Rodríguez JM. Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol. 2005 Oct;51(4):270-4. Epub 2005 Sep 20.</citation>
    <PMID>16187156</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiménez E, Marín ML, Martín R, Odriozola JM, Olivares M, Xaus J, Fernández L, Rodríguez JM. Is meconium from healthy newborns actually sterile? Res Microbiol. 2008 Apr;159(3):187-93. doi: 10.1016/j.resmic.2007.12.007. Epub 2008 Jan 11.</citation>
    <PMID>18281199</PMID>
  </results_reference>
  <results_reference>
    <citation>Myhre R, Brantsæter AL, Myking S, Gjessing HK, Sengpiel V, Meltzer HM, Haugen M, Jacobsson B. Intake of probiotic food and risk of spontaneous preterm delivery. Am J Clin Nutr. 2011 Jan;93(1):151-7. doi: 10.3945/ajcn.110.004085. Epub 2010 Oct 27.</citation>
    <PMID>20980489</PMID>
  </results_reference>
  <results_reference>
    <citation>Brantsaeter AL, Myhre R, Haugen M, Myking S, Sengpiel V, Magnus P, Jacobsson B, Meltzer HM. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am J Epidemiol. 2011 Oct 1;174(7):807-15. doi: 10.1093/aje/kwr168. Epub 2011 Aug 5.</citation>
    <PMID>21821542</PMID>
  </results_reference>
  <results_reference>
    <citation>Bertelsen RJ, Brantsæter AL, Magnus MC, Haugen M, Myhre R, Jacobsson B, Longnecker MP, Meltzer HM, London SJ. Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases. J Allergy Clin Immunol. 2014 Jan;133(1):165-71.e1-8. doi: 10.1016/j.jaci.2013.07.032. Epub 2013 Sep 10.</citation>
    <PMID>24034345</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeganegi M, Watson CS, Martins A, Kim SO, Reid G, Challis JR, Bocking AD. Effect of Lactobacillus rhamnosus GR-1 supernatant and fetal sex on lipopolysaccharide-induced cytokine and prostaglandin-regulating enzymes in human placental trophoblast cells: implications for treatment of bacterial vaginosis and prevention of preterm labor. Am J Obstet Gynecol. 2009 May;200(5):532.e1-8. doi: 10.1016/j.ajog.2008.12.032. Epub 2009 Mar 14.</citation>
    <PMID>19285652</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Bo Jacobsson</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>probiotic</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

